EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSAPOG00000000538
Gene Symbol: GRIK1
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSAPOG00000004584
Gene Symbol: GRIK2
1 Cross references
252 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSAPOG00000013986
Gene Symbol: GRIK2
3 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSAPOG00000024373
Gene Symbol: GRIK3
4 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSAPOG00000007132
Gene Symbol: GRIK4
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAPOG00000017326
Gene Symbol: GRIK5
3 Cross references
258 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAPOG00000023635
Gene Symbol: GRIK5
3 Cross references
263 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSAPOG00000005417
Gene Symbol: GRM2
3 Cross references
210 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAPOG00000009946
Gene Symbol: GRM4
3 Cross references
214 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAPOG00000015361
Gene Symbol: GRM4
3 Cross references
200 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSAPOG00000018862
Gene Symbol: GRM5
4 Cross references
216 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSAPOG00000023180
Gene Symbol: LOC110955409
3 Cross references
252 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).